Assessing endgame strategies for the elimination of lymphatic filariasis: A model-based evaluation of the impact of DEC-medicated salt

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Smith, Morgan E ^a   Singh, Brajendra K ^a   Michael, Edwin ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLCARBAMAZINE; SODIUM CHLORIDE;

ANIMAL; BAYES THEOREM; BRUGIA MALAYI; CHEMISTRY; COMPARATIVE STUDY; DISEASE ERADICATION; DRUG EFFECT; HUMAN; LYMPHATIC FILARIASIS; TRANSMISSION; WUCHERERIA BANCROFTI;

ANIMALS; BAYES THEOREM; BRUGIA MALAYI; DIETHYLCARBAMAZINE; DISEASE ERADICATION; ELEPHANTIASIS, FILARIAL; HUMANS; SODIUM CHLORIDE; WUCHERERIA BANCROFTI;

EID: 85026914488     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-07782-9     Document Type: Article

References (59)

1. World Health Organization. Monitoring and epidemiological assessment of mass drug administration in the global programme to eliminate lymphatic filariasis: a manual for national elimination programmes. (2011).
2. World Health Organization. Global programme to eliminate lymphatic filariasis: progress report, 2014. Weekly Epidemiological Record 38, 489-504 (2015).
3. Kastner, R. J., Stone, C. M., Steinmann, P., Tanner, M. & Tediosi, F. What is needed to eradicate lymphatic filariasis? A model-based assessment on the impact of scaling up mass drug administration programs. PLoS Negl Trop Dis 9, e0004147 (2015).
4. Michael, E. & Singh, B. K. Heterogeneous dynamics, robustness/fragility trade-offs, and the eradication of the macroparasitic disease, lymphatic filariasis. BMC medicine 14, 1 (2016).
5. Irvine, M. A. et al. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study. The Lancet Infectious Diseases (2016).
6. Esterre, P., Plichart, C., Sechan, Y. & Nguyen, N. L. The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort. Tropical medicine & International health 6, 190-195 (2001).
7. Ramaiah, K. D. & Vanamail, P. Surveillance of lymphatic filariasis after stopping ten years of mass drug administration in rural communities in south India. Trans. R. Soc. Trop. Med. Hyg. 107, 293-300 (2013).
8. Richards, F. O. et al. Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria. PLoS Negl Trop Dis 5, e1346 (2011).
9. Simonsen, P. E. et al. Lymphatic filariasis control in Tanga Region, Tanzania: status after eight rounds of mass drug administration. Parasites & vectors 7, 1 (2014).
10. Gambhir, M. & Michael, E. Complex ecological dynamics and eradicability of the vector borne macroparasitic disease, lymphatic filariasis. PLoS One 3, e2874 (2008).
11. Snow, L. & Michael, E. Transmission dynamics of lymphatic filariasis: density?dependence in the uptake of Wuchereria bancrofti microfilariae by vector mosquitoes. Med. Vet. Entomol. 16, 409-423 (2002).
12. Snow, L., Bockarie, M. & Michael, E. Transmission dynamics of lymphatic filariasis: vector?specific density dependence in the development of Wuchereria bancrofti infective larvae in mosquitoes. Med. Vet. Entomol. 20, 261-272 (2006).
13. Churcher, T., Ferguson, N. & Basanez, M. Density dependence and overdispersion in the transmission of helminth parasites. Parasitology 131, 121-132 (2005).
14. Gurarie, D. & Seto, E. Y. Connectivity sustains disease transmission in environments with low potential for endemicity: modelling schistosomiasis with hydrologic and social connectivities. J. R. Soc. Interface 6, 495-508 (2009).
15. Klepac, P., Metcalf, C. J., McLean, A. R. & Hampson, K. Towards the endgame and beyond: complexities and challenges for the elimination of infectious diseases. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 368, 20120137 (2013).
16. Bockarie, M. J., Kelly-Hope, L. A., Rebollo, M. & Molyneux, D. H. Preventive chemotherapy as a strategy for elimination of neglected tropical parasitic diseases: endgame challenges. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 368, 20120144 (2013).
17. Thomsen, E. K. et al. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis. Clin. Infect. Dis. 62, 334-341 (2016).
18. Fan, P. C. Eradication of bancroftian filariasis by diethylcarbamazine-medicated common salt on Little Kinmen (Liehyu district), Kinmen (Quemoy) Islands, Republic of China. Ann. Trop. Med. Parasitol. 84, 25-33 (1990).
19. Freeman, A. R. et al. A community-based trial for the control of lymphatic filariasis and iodine deficiency using salt fortified with diethylcarbamazine and iodine. Am. J. Trop. Med. Hyg. 65, 865-871 (2001).
20. Meyrowitsch, D. W., Simonsen, P. E. & Makunde, W. H. Mass DEC chemotherapy for control of bancroftian filariasis: comparative efficacy of four strategies two years after start of treatment. Trans. R. Soc. Trop. Med. Hyg. 90, 423-428 (1996).
21. Narasimham, M. V. et al. Control of bancroftian filariasis by diethylcarbamazine medicated common salt in Karaikal, Pondicherry, India. J. Commun. Dis. 21, 157-170 (1989).
22. Provincial Institute of Parasitic Diseases. Field trial on control of bancroftian filariasis using common salt medicated with diethylcarbamazine. Chin Med J (Engl) 2, 365-371 (1976).
23. Rao, C., Panduranga Rao, P. & Russel, S. Control of bancroftian filariasis with common salt medicated with diethylcarbamazine in Lakshadweep. Indian J. Med. Res. 73, 865-873 (1981).
24. Reddy, G. S. & Venkateswaralu, N. Mass administration of DEC-medicated salt for filariasis control in the endemic population of Karaikal, south India: implementation and impact assessment. Bull. World Health Organ. 74, 85-90 (1996).
25. Meyrowitsch, D., Simonsen, P. & Makunde, W. Bancroftian filariasis: analysis of infection and disease in five endemic communities of north-eastern Tanzania. Annals of Tropical Medicine & Parasitology 89, 653-663 (1995).
26. De-jian, S., Xu-li, D. & Ji-hui, D. The history of the elimination of lymphatic filariasis in China. Infectious diseases of poverty 2, 1 (2013).
27. Gelband, H. Diethylcarbamazine salt in the control of lymphatic filariasis. Am. J. Trop. Med. Hyg. 50, 655-662 (1994).
28. Cao, W., der Ploeg, V., Catherina, P. B., Ren, Z. & Habbema, D. F. Success against lymphatic filariasis. World Health Forum 18, 17-20 (1997).
29. Singh, B. K. & Michael, E. Bayesian calibration of simulation models for supporting management of the elimination of the macroparasitic disease, Lymphatic Filariasis. Parasit vectors 8, 1-26 (2015).
30. Michael, E., Malecela-Lazaro, M. N., Kabali, C., Snow, L. C. & Kazura, J. W. Mathematical models and lymphatic filariasis control: endpoints and optimal interventions. Trends Parasitol. 22, 226-233 (2006).
31. Meyrowitsch, D. W., Simonsen, P. E. & Makunde, W. H. Mass diethylcarbamazine chemotherapy for control of bancroftian filariasis through community participation: comparative efficacy of a low monthly dose and medicated salt. Trans. R. Soc. Trop. Med. Hyg. 90, 74-79 (1996).
32. Meyrowitsch, D. W. & Simonsen, P. E. Long-term effect of mass diethylcarbamazine chemotherapy on bancroftian filariasis, results at four years after start of treatment. Trans. R. Soc. Trop. Med. Hyg. 92, 98-103 (1998).
33. Ottesen, E. A. Efficacy of diethylcarbamazine in eradicating infection with lymphatic-dwelling filariae in humans. Review of Infectious Diseases 7, 341-356 (1985).
34. Singh, B. K. et al. and others. In Sequential Modelling of the Effects of Mass Drug Treatments on Anopheline-Mediated Lymphatic Filariasis Infection in Papua New Guinea (PLoS One, 2013).
35. Gambhir, M. et al. Geographic and ecologic heterogeneity in elimination thresholds for the major vector-borne helminthic disease, lymphatic filariasis. BMC biology 8, 1 (2010).
36. Lahariya, C. & Tomar, S. S. How endemic countries can accelerate lymphatic filariasis elimination? An analytical review to identify strategic and programmatic interventions. Journal of vector borne diseases 48, 1 (2011).
37. Adinarayanan, S., Critchley, J. A., Das, P. K. & Gelband, H. Diethylcarbamazine (DEC)?medicated salt for community?based control of lymphatic filariasis. The Cochrane Library (2007).
38. Tisch, D. J., Michael, E. & Kazura, J. W. Mass chemotherapy options to control lymphatic filariasis: a systematic review. The Lancet infectious diseases 5, 514-523 (2005).
39. Bousema, T. et al. Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med 9, e1001165 (2012).
40. Michael, E. et al. Mathematical modelling and the control of lymphatic filariasis. The Lancet infectious diseases 4, 223-234 (2004).
41. Al-Awadi, A. R. et al. Guinea worm (Dracunculiasis) eradication: update on progress and endgame challenges. Trans. R. Soc. Trop. Med. Hyg. 108, 249-251 (2014).
42. Sabesan, S., Vanamail, P., Raju, K. & Jambulingam, P. Lymphatic filariasis in India: epidemiology and control measures. J. Postgrad. Med. 56, 232 (2010).
43. Shriram, A. et al. Diurnally subperiodic filariasis in India-prospects of elimination: precept to action? Parasitol. Res. 109, 1-8 (2011).
44. Indian Council of Medical Research. Lymphatic Filariasis. (2014).
45. Houston, R. Salt fortified with diethylcarbamazine (DEC) as an effective intervention for lymphatic filariasis, with lessons learned from salt iodization programmes. Parasitology 121, S161-S173 (2000).
46. Michael, E., Meyrowitsch, D. & Simonsen, P. Cost and cost effectiveness of mass diethylcarbamazine chemotherapy for the control of bancroftian filariasis: comparison of four strategies in Tanzania. Tropical Medicine & International Health 1, 414-426 (1996).
47. Michael, E. & Bundy, D. A. Herd immunity to filarial infection is a function of vector biting rate. Proc. Biol. Sci. 265, 855-860 (1998).
48. Lammie, P., Milner, T. & Houston, R. Unfulfilled potential: using diethylcarbamazine-fortified salt to eliminate lymphatic filariasis. Bull. World Health Organ. 85, 545-549 (2007).
49. Vadivel, S. Spatial dimensions of filariasis in Kumbakonam Control Unit, Tamil Nadu, India: A GIS approach. (2012).
50. Oscar, R. et al. Haiti National Program for the Elimination of Lymphatic Filariasis-A Model of Success in the Face of Adversity. PLoS neglected tropical diseases 8, e2915 (2014).
51. Fischer, P. U., King, C. L., Jacobson, J. A. & Weil, G. J. Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa. PLoS neglected tropical diseases 11, e0005163 (2017).
52. Raftery, A. E., Givens, G. H. & Zeh, J. E. Inference from a deterministic population dynamics model for bowhead whales. Journal of the American Statistical Association 90, 402-416 (1995).
53. Raftery, A. E. & Bao, L. Estimating and projecting trends in HIV/AIDS generalized epidemics using incremental mixture importance sampling. Biometrics 66, 1162-1173 (2010).
54. Spear, R. C. & Hubbard, A. In Modelling parasite transmission and control (eds Michael, E. & Spear, R. C.) 99-111 (Springer Science & Business Media, New York, New York, USA, 2010).
55. Griffin, J. T. et al. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med 7, e1000324 (2010).
56. Okumu, F. O. & Moore, S. J. Combining indoor residual spraying and insecticide-treated nets for malaria control in Africa: a review of possible outcomes and an outline of suggestions for the future. Malaria journal 10, 1 (2011).
57. Simonsen, P., Meyrowitsch, D., Makunde, W. & Magnussen, P. Bancroftian filariasis: the pattern of microfilaraemia and clinical manifestations in three endemic communities of northeastern Tanzania. Acta Trop. 60, 179-187 (1995).
58. McMahon, J. et al. Studies on the transmission and prevalence of bancroftian filariasis in four coastal villages of Tanzania. Annals of Tropical Medicine & Parasitology 75, 415-431 (1981).
59. Arnold, B. F. et al. Serological measures of malaria transmission in Haiti: comparison of longitudinal and cross-sectional methods. PloS one 9, e93684 (2014).